FDA's Oncologic Drugs Advisory Committee
Executive Summary
On Jan. 31 will discuss Burroughs Wellcome's Alkeran (melphalan) injection (NDA 20-207) for hyperthermic-isolated limb perfusion as an adjunct to surgery for locally-advanced malignant melanoma of the extremities and for palliative treatment of multiple melanoma. The committee will also review U.S. Bioscience's Ethyol (amifostine) injection (NDA 20-221) as a protective agent against toxicities from intensive regimens of platinum and alkylating agent chemotherapy. The meeting will start at 8 a.m. in Conference Rooms D & E at FDA's Parklawn Building. . . .